| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013 | 2307 | 2013 |
| Efficiency and power in genetic association studies PIW De Bakker, R Yelensky, I Pe'er, SB Gabriel, MJ Daly, D Altshuler Nature genetics 37 (11), 1217-1223, 2005 | 2061 | 2005 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1230 | 2017 |
| Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, ... Nature medicine 18 (3), 382-384, 2012 | 1095 | 2012 |
| Estimation of the multiple testing burden for genomewide association studies of nearly all common variants I Pe'er, R Yelensky, D Altshuler, MJ Daly Genetic Epidemiology: The Official Publication of the International Genetic …, 2008 | 953 | 2008 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 815 | 2015 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 722 | 2014 |
| Kinase fusions are frequent in Spitz tumours and spitzoid melanomas T Wiesner, J He, R Yelensky, R Esteve-Puig, T Botton, I Yeh, D Lipson, ... Nature communications 5 (1), 3116, 2014 | 634 | 2014 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 569 | 2014 |
| Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity H Beltran, R Yelensky, GM Frampton, K Park, SR Downing, ... European urology 63 (5), 920-926, 2013 | 568 | 2013 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 548 | 2016 |
| New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing JS Ross, K Wang, L Gay, R Al-Rohil, JV Rand, DM Jones, HJ Lee, ... The oncologist 19 (3), 235-242, 2014 | 523 | 2014 |
| Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer ER Plimack, RL Dunbrack, TA Brennan, MD Andrake, Y Zhou, ... European urology 68 (6), 959-967, 2015 | 502 | 2015 |
| D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer K Merenbakh-Lamin, N Ben-Baruch, A Yeheskel, A Dvir, ... Cancer research 73 (23), 6856-6864, 2013 | 456 | 2013 |
| Genome-wide discovery of transcriptional modules from DNA sequence and gene expression E Segal, R Yelensky, D Koller Bioinformatics-Oxford 19 (1), 273-282, 2003 | 364 | 2003 |
| Evaluating and improving power in whole-genome association studies using fixed marker sets I Pe'er, PIW de Bakker, J Maller, R Yelensky, D Altshuler, MJ Daly Nature genetics 38 (6), 663-667, 2006 | 345 | 2006 |
| Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms R Rampal, J Ahn, O Abdel-Wahab, M Nahas, K Wang, D Lipson, GA Otto, ... Proceedings of the National Academy of Sciences 111 (50), E5401-E5410, 2014 | 332 | 2014 |
| Optimization of multigene analysis of tumor samples D Lipson, GA Otto, AN Parker, PJ Stephens, SR Downing, M Jarosz, ... US Patent 9,340,830, 2016 | 326 | 2016 |
| The distribution of BRAF gene fusions in solid tumors and response to targeted therapy JS Ross, K Wang, J Chmielecki, L Gay, A Johnson, J Chudnovsky, ... International journal of cancer 138 (4), 881-890, 2016 | 307 | 2016 |
| Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting J He, O Abdel-Wahab, MK Nahas, K Wang, RK Rampal, AM Intlekofer, ... Blood, The Journal of the American Society of Hematology 127 (24), 3004-3014, 2016 | 303 | 2016 |
Doron LipsonCSO, Ultima GenomicsCorreu electrònic verificat a ultimagen.com